%0 Journal Article
%T Clinical profile, treatment, and outcomes of patients with mantle cell lymphoma treated in a tertiary care center in South India
%A Kadabur Lokesh
%A Sunny Garg
%A Lakshmaiah Kuntegowdanahalli
%A Govinda Kanakasetty
%A Premalata Srinivasamurthy
%A Suparna Rao
%A Linu Jacob
%A Loknatha Dasappa
%A Suresh Babu Chikkadasappa
%A Rudresha Halleshappa
%A Rajeev Krishnappa
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2016
%V 5
%N 5
%R 10.4103/2278-0513.197863
%P 369-373
%X Introduction: Mantle cell lymphoma has an aggressive course, with unfavorable outcomes. Subjects and Methods: A retrospective analysis was undertaken and 77 cases were identified between 2009 and 2014. Results: Median age was 55 years with a male to female ratio of 6:1. Patients with pure nodal disease at presentation were fewer than with extranodal disease (53.2%). Most common extranodal site was bone marrow. A number of patients with low-, low-intermediate, high-intermediate, and high-risk International Prognostic Index (IPI) scores were 6, 24, 22, and 25. Treatment consisted of cyclophosphamide,hydroxydaunorubicin, oncovin, prednisolone (CHOP) or R-CHOP regimens. Median survival was 21 months. Median overall survival with early and advanced disease was 31 and 18 months (P = 0.02). Patients who received R-CHOP survived better than those given CHOP, 30 and 16 months (P = 0.0002). There was no difference in survival with respect to age, gender, extranodal, or bone marrow involvement. Conclusions: Most patients presented with extranodal disease, advanced stage, and high IPI. Although rituximab has improved survival, intensive chemotherapy would be required to improve survival.
%U https://ccij-online.org/article/clinical-profile,-treatment,-and-outcomes-of-patients-with-mantle-cell-lymphoma-treated-in-a-tertiary-care-center-in-south-india-619